CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 310 enrolled
Drug / intervention
Zoledronic acid +3 moredrug
Likely dose
Zoledronic acid 5.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02589600
NCT02589600Phase 4Completed
CompareCT.gov

ZEST II for Osteoporotic Fracture Prevention

Susan L. Greenspan·interventional·Posted Oct 28, 2015·Updated Sep 26, 2023

In Brief

A Phase 4 clinical trial evaluating Zoledronic acid, vitamin D, and 2 other interventions for Osteoporotic Fractures and Osteoporosis, Postmenopausal. Completed, enrolled 310 participants across 1 site.

Detailed Summary

The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporotic Fractures, Osteoporosis, Postmenopausal
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute on Aging (NIA)

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 28, 2015
Enrollment StartJan 1, 2016
Primary CompletionJun 22, 2022
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 10.7 years ago

Interventions

Zoledronic aciddrug

Annual intravenous 5.0 mg

vitamin Ddietary

800 IU daily

calciumdietary

approximately 1200 mg (dietary and supplement)

Salineother

Annual intravenous saline placebo